Phase I and pharmacokineticsA phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
Under an Elsevier user license
open archive
Keywords
capecitabine
CI-994
dose-limiting toxicity
histone deacetylase inhibitor
pharmacokinetics
phase I study
Cited by (0)
Copyright © 2004 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.